Chromatrap®, a business unit of Porvair Sciences, has developed a new protocol that further extends the many advantages of its popular Chromatin Immunoprecipitation Sequencing (ChIP-seq) assay kits.

Key developments for the Chromatrap® ChIP-seq kit (version 1.2) include high quality chromatin can now be achieved via sonication or enzymatic digestion ; high and low abundant enrichment is possible from small chromatin samples ; improved antibody binding ; greater chromatin loading flexibility and the ability to use increased slurry volumes for difficult samples.

Chromatrap’s® ChIP-seq kit uses solid state technology in parallel with high throughput sequencing to deliver a streamlined ChIP-seq protocol from small cell numbers and low chromatin concentrations. Specifically adapted for broader chromatin concentrations, Chromatrap® ChIP-seq combines the dynamic range of Chromatrap® with the downstream analysis power of deep sequencing. This allows faster, more reproducible genome wide identification of TF binding sites and specific DNA associated protein modifications. With no limitation in scale or resolution, Next Generation Sequencing can elucidate the role of TFs and epigenetic marks on gene transcription and epigenetic chromatin status.

The Chromatrap® ChIP-seq kit allows the user to perform up to 24 ChIP assays from cell collection through to immunoprecipitation, including up to 10 chromatin sample preparations. The kit provides all of the major components required for performing ChIP assays to obtain high quality DNA for Next Generation Sequencing library preparation. With the Chromatrap® ChIP-seq kit you can sequence from as little as 1-50 µg of chromatin and perform up to 10 library preparations form a single IP. A complete ChIP-seq assay can be completed in just five days. With selective and sensitive enrichment of low chromatin loading and optimised elution buffer chemistry the new version 1.2 of the Chromatrap’s® ChIP-seq kit enables preparation of high quality and quantity of immunoprecipitated DNA.

more about porvair sciences

more news from porvair sciences